Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Supplementary Figure S3 from Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study

Yvette Drew,Jae-Weon Kim,Richard T. Penson,David M. O'Malley,Christine Parkinson,Patricia Roxburgh,Ruth Plummer,Seock-Ah Im,Martina Imbimbo,Michelle Ferguson,Ora Rosengarten,Neeltje Steeghs,Min Hwan Kim,Einav Gal-Yam,Daliah Tsoref,Jae-Hoon Kim,Benoit You,Maja De Jonge,Roy Lalisang,Eelke Gort,Sara Bastian,Kassondra Meyer,Laura Feeney,Nigel Baker,Mei-Lin Ah-See,Susan M. Domchek,Susana Banerjee

crossref（2024）

Cited 0|Views9
No score
Abstract
Individual patient outcomes in the (A) non-gBRCAm doublet cohort and (B) non-gBRCAm triplet cohort
More
Translated text
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined